Clinical trial
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or…
NCT00298272 · Biogen, Industry · Terminated
Key facts
| NCT number | NCT00298272 |
|---|---|
| Title | Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis |
| Official title | A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis |
| Lead sponsor | Biogen, Industry |
| Collaborators | Hoffmann-La Roche Industry Genentech, Inc. |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Biological, Dietary Supplement, Drug |
| Interventions | IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate |
| Enrollment | 54 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Jul 1, 2011 |
| First posted | Mar 2, 2006 |
| Last update posted | Sep 28, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: